Cytogen
Executive Summary
Princeton, New Jersey-based R&D biopharmaceutical company announces a public offering of 2 mil. shares of common stock at $ 14.75 per share: Lehman Brothers and Merrill Lynch are co-managing. Proceeds will be used for product clinical trials and commercialization, and marketing and sales. Cytogen currently is developing monoclonal antibody-based imaging agents and treatments for cancer.